Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

The Mescal family’s lives have changed tenfold in recent years, with two of the children forging careers in the spotlight and even mum Dearbhla becoming a well-known face. Dearbhla, who was diagnosed ...

Multiple myeloma was once viewed as an incurable diagnosis, but Ameet Patel, MD, of Florida Cancer Specialists & Research ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

Biologic heterogeneity in myeloma supports subtype-specific approaches, and t(4;14) defines a clinically meaningful subset with distinct pathway activation and historically aggressive behavior.